Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated <i>KRAS</i> G12C-Reference-Cited by-同舟云学术

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C

Published:2023-12-07 Issue:23 Volume:389 Page:2125-2139
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Fakih Marwan G.¹,Salvatore Lisa¹^ORCID,Esaki Taito¹,Modest Dominik P.¹,Lopez-Bravo David P.¹,Taieb Julien¹,Karamouzis Michalis V.¹,Ruiz-Garcia Erika¹,Kim Tae-Won¹,Kuboki Yasutoshi¹,Meriggi Fausto¹,Cunningham David¹,Yeh Kun-Huei¹,Chan Emily¹,Chao Joseph¹,Saportas Yaneth¹,Tran Qui¹,Cremolini Chiara¹,Pietrantonio Filippo¹

Affiliation:

1. From Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte (M.G.F.), and Amgen, Thousand Oaks (E.C., J.C., Y.S., Q.T.) — both in California; Oncologia Medica, Università Cattolica del Sacro Cuore, and Oncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome (L.S.), the Oncology Department, Fondazione Poliambulanza Istituto Ospedaliero, Brescia (F.M.), the Department of Translational Research and New...

Funder

Amgen

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2308795

Reference34 articles.

1. Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer

2. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors

3. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

4. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Third-line treatment and beyond in metastatic colorectal cancer: What do we have and what can we expect?;Critical Reviews in Oncology/Hematology;2024-10

2. Breaking barriers: the latest insights into KRAS G12C inhibitors;Future Oncology;2024-09-12

3. Enhancing efficacy of the MEK inhibitor trametinib with paclitaxel inKRAS-mutated colorectal cancer;2024-09-06

4. Metabolic Response to Small Molecule Therapy in Colorectal Cancer Tracked with Raman Spectroscopy and Metabolomics;Angewandte Chemie;2024-09-05

5. Metabolic Response to Small Molecule Therapy in Colorectal Cancer Tracked with Raman Spectroscopy and Metabolomics;Angewandte Chemie International Edition;2024-09-05